Focusing on the combination of basic theories of Chinese medicine and the development results of modern scientific research, Li Jie chose lymphocyte and tumor cell apoptosis as the entry point, and earlier proposed that the advantage of Chinese medicine in the prevention and treatment of tumors lies in multi-targets. In response to the clinical problem of tumor metastasis, he took the lead in carrying out the research on the interventional effect and molecular mechanism of different combinations of Qi and blood on tumor metastasis, and assisted his supervisor, Dr. Sun Guizhi, in declaring and winning the bidding of three National Natural Science Funds and one scientific research project for the special fund of central health care, and participated in the completion of the National Tenth Five-Year Plan and the National Eleventh Five-Year Plan of Scientific and Technological Support for Tumor Research. He also participated as a key person in the completion of the National 15th Chinese Medicine Tumor Science and Technology Tackling Project and the National 11th Five-Year Plan of Science and Technology Support Program to declare and win the bid for the demonstration of Chinese medicine comprehensive treatment program for major diseases.
In 2004, he was selected for the Beijing Science and Technology Rising Star Cultivation A Program based on the National Natural Science Foundation of China.
In 2006, she won a bid for the National Natural Science Youth Fund as a project leader. From January 2007 to December 2008, she was funded by the National Institutes of Health (NIH) and the Ministry of Science and Technology of China, and was sent by Guang'anmen Hospital to the National Cancer Institute's (NCI) Laboratory of Molecular Immunomodulation for joint training. As the first postdoctoral fellowship in China and the United States specializing in Chinese medicine and tumor prevention and treatment, Guang'anmen Hospital sent him to the National Cancer Institute (NCI) in the United States for joint training. Under the guidance of Dr. Joost J Oppenheim, a famous molecular immunology expert in the United States, he carried out research on the immunomodulatory effect of traditional Chinese medicine on breast cancer and cellular and molecular mechanisms of breast cancer, and his thesis was awarded the NCI 2008 Postdoctoral Thesis Award.
Returning to China at the end of 2008, in addition to the integrated diagnosis and treatment of common malignant tumors, she also carries out gastroscopic diagnosis of precancerous lesions of gastric cancer and traditional Chinese medicine (TCM) interventions on Tuesday mornings, and applies the theory of TCM's "treating the disease before it gets sick" to the diagnosis and treatment of precancerous lesions of digestive system tumors.
At present, we adhere to the academic idea of "supporting the right and cultivating the root" as the mainstay of TCM treatment of tumors, combining identification of diseases with identification of evidence, and taking the immunosuppressive cells of the body as the entry point, we have carried out in-depth research on the mechanism of evidence-based medicine and cellular molecular immune regulation to prevent and control tumor recurrence and metastasis by supporting the right and cultivating the root of tumors and to reduce toxicity and increase the effect of radiotherapy.
As the main accomplisher, he was awarded the second prize of Beijing Science and Technology Progress in 2007-2008, and the first prize of Science and Technology Progress of China Academy of Traditional Chinese Medicine, China Society of Integrative Medicine, and China Society of Traditional Chinese Medicine, respectively.
In recent years, he has published more than 20 articles in the journals of "China Cancer Clinic, China Journal of Tumor Biotherapy, China Cancer, China Surgery of Integrative Medicine and Western Medicine, and International Immunopharmacology", etc. He has also published a series of tumor-related articles on "Health Times". Health Times", and 18 articles on tumor-related popularization. He is the editor-in-chief of "Diagnosis and Treatment of Common Diseases in Oncology", "TCM Tumor Prevention and Control Series - TCM Tumor Prevention and Control of Head and Neck and Bone and Soft Tissue Tumors", and other series of books. Currently, he is also the executive editorial board member of China Tissue Engineering Research and Clinical Rehabilitation (formerly China Clinical Rehabilitation), and a member of the Academic Committee of Fresh Drugs of China Cancer Research Foundation.